Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro

Memorias do Instituto Oswaldo Cruz

Volumn 104, Issue 3, 2009, Pages 462-467

  de Souza, Claudia Teresa Vieira ^a   Hökerberg, Yara Hahr Marques ^a   Pacheco, Sandro Javier Bedoya ^a   Rolla, Valéria Cavalcanti ^b   Passos, Sonia Regina Lambert ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b INSTITUTO EVANDRO CHAGAS   (Brazil)

Author keywords

Chemoprophylaxis; Clinical trial (publication type); HIV 1; Isoniazid; Treatment outcome; Tuberculosis

Indexed keywords

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67649537622     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/s0074-02762009000300011     Document Type: Article

References (30)

1. ATS - American Thoracic Society 2000. Target tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161: S221-S247.
2. Blumberg HM, Leonard MK, Jasmer RM 2005. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 293: 2776-2784.
3. Bucher HC, Griffith L E, Guyatt GH, Sudre P, Naef M, Sendi P, Battegay M 1999. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 13: 501-507.
4. Casado JL, Moreno S, Fortún J, Antela A, Quereda C, Navas E, Moreno A, Dondra F 2002. Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients. Clin Infect Dis 34: 386-389.
5. CDC - Centers for Disease Control and Prevention 1996. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep 45: 1-18.
6. CDC - Centers for Disease Control and Prevention 2003. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States. MMWR Morb Mortal Wkly Rep 52: 735-739.
7. Churchyard GJ, Fielding K, Charalambous S, Day JH, Corbett EL, Hayes RJ, Chaisson RE, De Cock KM, Samb B, Grant AD 2003. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS 17: 2063-2070.
8. de Castro Toledo AC Jr, Greco DB, Antunes CM 2000. Risk factors for tuberculosis among human immunodeficiency virus-infected persons. A case-control study in Belo Horizonte, Minas Gerais, Brazil (1985-1996). Mem Inst Oswaldo Cruz 95: 437-443.
9. de Pinho AM, Santoro-Lopes G, Harrison LH, Schechter M 2001. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS 15: 2129-2135.
10. Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Ricknbach M, Furrer H, Swiss HIV Cohort Study 2007. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment and retroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 44: 103-104.
11. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B 2007. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 21: 1441-1448.
12. Gourevictch MN, Hartel D, Selwyn PA, Schoenbaum EE, Klein RS 1999. Effectiveness of isoniasid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. AIDS 13: 2069-2074.
13. Grant AD, Charalambous S, Fielding KL, Day JH, Corbett EL, Chaisson RE, De Cock KM, Hayes RJ, Churchyard GJ 2005. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa. JAMA 293: 2719-2725.
14. Hiransuthikul N, Nelson KE, Hiransuthikul P, Vorayingyong A, Paewplot R 2005. INH preventive therapy among adult HIV-infected patients in Thailand. Int J Tuberc Lung Dis 9: 270-275.
15. Last JM 2001. A Dictionary of Epidemiology, 4th ed., Oxford University Press, New York, 224 pp.
16. Lienhardt C, Fielding K, Sillah J, Tunkara A, Donkor S, Manneh K, Warndorff D, McAdam KP, Bennett S 2003. Risk factors for tuberculosis infection in the Sub-Saharan Africa: a contact study in the Gambia. Am J Respir Crit Care Med 168: 448-455.
17. Moulton LH, Golub JE, Durovni B, Cavalcante SC, Pacheco AG, Saraceni V, King B, Chaisson RE 2007. Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention. Clin Trials 4: 190-199.
18. MS - Ministério da Saúde 2007. [homepage on the Internet]. Recomendações para a terapia anti-retroviral em adultos e adolescentes infectados pelo HIV. Secretaria de Vigilância em Saúde/Programa Nacional de DST e Aids [updated 2008 April 13; cited 2008 May 6] Available from: (http://www.aids.gov.br/data/documents/oredDocuments/%7BB8EF5DAF-23AE-4891-AD36-553A3174%7D/%7B8CA22668-AE86-470E-BEC293661DBBDEA1%7D/consenso%20-%20adultos%20adoles-centes%20infectados%20hiv%202006.pdf).
19. Neuenschwander BE, Zwahlen M, Kim SJ, Lee EG, Rieder HL 2002. Determination of the prevalence of infection with Mycobacterium tuberculosis among persons vaccinated against Bacillus Calmette-Guérin in South Korea. Am J Epidemiol 155: 654-662.
20. Rivero A, López-Cortés L, Castillo R, Verdejo J, García MA, Martínez-Marcos FJ, Díez F, Escribano JC, Canueto J, Lozano F, Pasquau J, Hernández JJ, Márquez M, Kindelán JM, Grupo Andaluz para el estudio de las Enfermedades Infecciosas (GAEI) 2007. Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients. Enferm Infecc Microbiol Clin 25: 305-310.
21. Sadaphal P, Astemborski J, Graham NM, Sheely L, Bonds M, Madison A, Vlahov D, Thomas DL, Sterling TR 2001. Isoniazid preventive therapy, hepatitis C virus infection and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis 33: 1687-1691.
22. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M 2002. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 34: 543-546.
23. Sebastian MS, Bothamley GH 2000. Tuberculosis preventive therapy: perspective from a multi-ethnic community. Respir Med 94: 648-653.
24. Szakacs TA, Wilson D, Cameron DW, Clark M, Kocheleff P, Muller FJ, McCarthy AE 2006. Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infect Dis 6: 97.
25. Tissot F, Zanetti G, Francioli P, Zellweger JP, Zysset F 2005. Influence of Bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 40: 211-217.
26. Volmink J, Garner P 2003. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 1: CD003343.
27. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM 2002. A meta-analysis of the effect of Bacille Calmette-Guérin vaccination on tuberculin skin test measurements. Thorax 57: 804-809.
28. Whalen CC 2005. Diagnosis of latent tuberculosis infection: measure for measure. JAMA 293: 2785-2787.
29. WHO - World Health Organization 2007. Global tuberculosis control: surveillance, planning, financing: WHO Report 2007. [monograph on the Internet]. [cited 2007 September 7]. Available from: (http://www.who.int/tb/publications/global_report/2007/pdf/full.pdf).
30. Woldehanna S, Volmink J 2004. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 1: CD000171.